Imagine a world where a single treatment could manage type 2 diabetes or obesity for months at a time, freeing patients from the burden of daily medications and the frustrating cycle of weight regain. This isn’t a distant dream but a potential reality being shaped by Junevity, a biotechnology
What if a single batch of cells could save thousands of lives without the wait and expense of custom-made treatments? This isn’t a distant dream but a tangible reality unfolding in the realm of allogeneic cell therapy, where “off-the-shelf” solutions derived from donor cells are poised to
What if the complex journey of turning a groundbreaking biologic into a life-saving therapy could be transformed into a streamlined, efficient process? In a world where biopharmaceutical development faces unprecedented challenges, a powerful collaboration between Rentschler Biopharma and Coriolis
Regulated bioprocesses rise or fall on the quiet details—additives, excipients, and media choices that shape every run and either unlock reproducibility or invite costly variability when scale-up and compliance converge. In that context, high‑purity methylcellulose has reemerged as a practical
What if the very speed that delivered lifesaving vaccines also cemented a single-technology playbook that looks nimble in peacetime but brittle under pressure when the next pathogen demands different strengths and a steadier supply chain than speed alone can provide? The COVID-19 race crowned mRNA
Rising failure rates for single-mechanism therapies in heterogeneous solid tumors have pushed oncology beyond single-target tinkering and into platform-centric thinking that prizes modularity, combinability, and consistent manufacturability across programs. In this shift, antibody-drug conjugates
